Good
Partially Aligned
Patient Risk:
Low
Summary
Most listed adverse-effect categories are supported by the provided label excerpt (nervous system, gastrointestinal, hematologic, renal failure, and encephalopathy/seizure/confusion). However, the label excerpt does not support the specific phrasing of “infrequent” for multiple items and does not explicitly describe “acyclovir-induced nephropathy … if left untreated” as a rare serious adverse effect.
Category Scores
Accurate Statements
Acyclovir has infrequent adverse effects including neurological problems such as headache, dizziness, confusion, and seizures.
Supported by “Observed During Clinical Practice” nervous section listing headache, dizziness, confusion, seizure, encephalopathy, agitation/delirium, and “may be marked…in…renal impairment.” Also supported generally by “General” including headache and by label listing “Seizure” under Nervous.
Acyclovir has infrequent adverse effects including gastrointestinal issues such as nausea, vomiting, diarrhea, and abdominal pain.
Supported by clinical trial section noting nausea and/or vomiting and diarrhea; and by “Digestive” listing diarrhea, gastrointestinal distress, nausea (abdominal pain not explicitly listed).
Acyclovir can cause renal problems, including kidney damage, particularly in patients with pre-existing kidney disease.
Supported by “Observed During Clinical Practice” listing renal failure and by “Nervous” section noting CNS symptoms may be marked in patients with renal impairment; label also provides precautions recommending dosage adjustment in renal impairment.
Acyclovir has infrequent adverse effects including hematological issues such as anemia, leukopenia, and thrombocytopenia.
Supported by “Hematologic and Lymphatic” listing anemia, leukopenia, thrombocytopenia.
Acyclovir can cause a rare but serious adverse effect called acyclovir-induced encephalopathy characterized by confusion, agitation, and seizures.
Supported by “Nervous” listing encephalopathy, confusion, agitation, and seizure (though the label does not use the term “acyclovir-induced encephalopathy” nor explicitly state “rare”).
Unsupported Statements
Acyclovir has infrequent adverse effects including neurological problems such as headache, dizziness, confusion, and seizures.
The label excerpt lists these events but does not provide frequency language such as “infrequent” for the post-approval/observed-during-practice events.
Acyclovir has infrequent adverse effects including gastrointestinal issues such as nausea, vomiting, diarrhea, and abdominal pain.
“Infrequent” frequency is not provided for the observed-during-clinical-practice digestive events, and “abdominal pain” is not explicitly listed in the provided excerpt (only gastrointestinal distress/nausea/diarrhea).
Acyclovir can cause renal problems, including kidney damage, particularly in patients with pre-existing kidney disease.
The excerpt supports renal impairment-related caution and renal failure events, but it does not explicitly characterize renal injury as “particularly” occurring in pre-existing kidney disease.
Acyclovir has infrequent adverse effects including hematological issues such as anemia, leukopenia, and thrombocytopenia.
The excerpt lists these hematologic events without providing “infrequent” frequency language.
Acyclovir can cause a rare but serious adverse effect called acyclovir-induced encephalopathy characterized by confusion, agitation, and seizures.
The excerpt supports the constituent events (encephalopathy/confusion/agitation/seizure) but does not explicitly state “rare” or use the coined term “acyclovir-induced encephalopathy.”
Acyclovir can cause a rare but serious adverse effect called acyclovir-induced nephropathy that can lead to kidney failure if left untreated.
The excerpt lists “renal failure” but does not describe a distinct “acyclovir-induced nephropathy” entity, does not state “rare,” and does not state a progression “if left untreated.”
Contradictions
Important Omissions
The label excerpt does not support the specific frequency descriptor “infrequent” used across multiple claims; more accurate label-consistent phrasing would avoid asserting frequency for observed-during-clinical-practice events.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Claims largely reflect adverse-event types present in the label excerpt. The main potential issue is over-specific framing (e.g., “rare,” “infrequent,” and “if left untreated”) that is not supported by the provided labeling text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Several claims add unsupported frequency/phrasing ("infrequent", "rare") and introduce a coined renal entity (“acyclovir-induced nephropathy”) and a progression narrative (“if left untreated”) not present in the provided label excerpt.
Suggested Improvement
Remove or qualify frequency wording not stated in the label excerpt (e.g., avoid “infrequent/rare” for observed post-approval events). For renal effects, reference “renal failure” and label-supported renal impairment precautions without asserting a specific “nephropathy” term or an untreated progression.